anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Surgical Image Processing and Reporting System (SIPORS) will be able to record the procedure along with transcribing the video into text through Artificial Intelligence. Artificial Intelligence is built into the system by using cameras. Through this, the system will write operative reports for doctors by going through a Writing Module in the system. Post-surgery, the doctors will be able to review the report written by the system and make edits to it. Since this is an artificial intelligence system, it will be able to learn and save the new edits the doctor makes. It will not be necessary to make this same edit again. As of now, doctors are burdened and exhausted due to the several hours spent writing the operative report. Therefore, we invented this system that reduces the time it requires to write the report.
A health long-term tracking system for the elderly is provided in the present disclosure. The health long-term tracking system for the elderly includes a health information center, a hospital-end device, a clinic-end device, a community-end device and a personal device. The personal device or the community-end device is configured to send a daily physiological data of an elder to the health information center. After the health information center interprets the daily physiological data, the health information center can automatically send an advice message back or send the daily physiological data to the hospital-end device and/or the clinic-end device. The health information center keeps on tracking, and provides personal information and advice according to the change of the daily physiological data. The elder is able to make a live remote communication with the hospital-end device or the clinic-end device by using the personal device or the community-end device, so as to obtain proper medical advices or health information. Therefore, the health habits of the elderly can be developed step by step.
A system and computer implemented method for use in determining the deviation-of an intra-operative position of an orthopaedic implant from a planned position is described. The position of the orthopaedic implant in the bone is defined by a plurality of implant position parameters. The distance of a plurality of anatomical features in a three dimensional model of the surface of the bone relative to a model of the implant at a first position is calculated. The first position corresponds to a first set of values for the implant position parameters. The distance of the plurality of anatomical features to a model of the implant at a second position in the bone is calculated. The second position corresponds to a second set of values for the implant position parameters, and the second position is different to the first position.
BACKGROUND: The COVID-19 pandemic has experienced various phases including outbreaks, a global health crisis, and eventual de-escalation from a public health emergency of international concern, significantly affecting the delivery and utilization of healthcare services. This study aimed to evaluate the impact of the COVID-19 pandemic on the coverage rate of routine immunization in children under varying prevalence conditions.
METHODS: We conducted a retrospective, population-based cohort study in Beijing, China, utilizing stratified random sampling by birthdate to obtain a sample of 29,811 participants. Subjects were categorized into four cohorts based on when they became eligible for vaccination: the Pre-COVID Period cohort, the COVID-19 Low Epidemic Period cohort, the COVID-19 Surging Period cohort, and the COVID-19 Slowing Down Period cohort. A one-month follow-up was conducted. Cox proportional hazards model was employed to examine associations between the COVID-19 epidemic status and timely vaccination.
RESULTS: Participants age-eligible for vaccination during the COVID-19 Low Epidemic Period demonstrated higher rates of timely vaccination (HR 1.18, 95% CI 1.15-1.22) compared to those eligible during the Pre-COVID Period. Conversely, those eligible during the COVID-19 Surging Period displayed lower rates (HR 0.73, 95% CI 0.66-0.82). No significant difference in vaccination timeliness was observed for those eligible during the COVID-19 Slowing Down Period in comparison to the Pre-COVID Period (HR 0.99, 95% CI 0.91-1.09). By the end of May 2023, DTP3 rate among eligible children during the COVID-19 Surging Period had surpassed 90%.
CONCLUSIONS: Significantly declining rates of timely vaccination were observed during the COVID-19 Surging Period, which lasted two months, but not during the nearly three-year-long COVID-19 Low Epidemic Period. An upward trend in vaccination timeliness followed, culminating in a return to baseline levels over the subsequent 3-4 months. Our findings suggested that the pandemic exerted a decreasing and recoverable impact on the coverage rate of routine immunizations in China.
Extrahepatic metastasis of hepatocellular carcinoma has recently been paradoxically increasing due to increased survival with effective locoregional therapies. Sorafenib is the first systemic agent that has demonstrated a significant survival benefit in patients with advanced HCC; however, the modest improvement of 3 months is far from satisfactory. There is no convincing evidence, to date, that systemic chemotherapy when tumor progresses after sorafenib therapy improves overall survival. The combination of anticancer agents is important to achieve favourable clinical results. For patients with metastatic liver cancer or HCC, some studies have discussed the effectiveness of 5-fluorouracil/mitomycin(FM). However, few studies have examined the actual FM regimen for HCC.

The aim of this study is to evaluate the efficacy of 5-fluorouracil/mitomycin for the patients with pulmonary metastasis of hepatocellular carcinoma who had progressive disease with sorafenib.
PURPOSE OF REVIEW: This review aims to summarize the current state of the art and future directions in optimal long-term anticoagulation following acute pulmonary embolism (PE).
RECENT FINDINGS: Actual studies and guidelines underscore the preference for direct oral anticoagulants (DOAC) in standard therapeutic doses for maintenance therapy post-PE, while considering patient-specific factors and dose-reduction criteria. Risk stratification should always include the assessment of concomitant trigger- or risk factors regarding their strength and persistence. The use of tools like specific scores can facilitate the identification of optimal candidates for long-term therapy, emphasizing once more personalized approaches and strategies. Special patient groups, such as cancer associated thrombosis, chronic thromboembolic pulmonary hypertension or antiphospholipid syndrome require even more tailored therapy approaches.
SUMMARY: Optimal long-term anticoagulation post-PE should be guided by straightforward and individual risk assessment strategies. The array of indications for DOACs has gotten wider in last years, also within special patient groups. Still, chronic thromboembolic pulmonary hypertension and antiphospholipid syndrome remains domain of vitamin K agonists.
The present invention relates to an oral taking traditional Chinese medicine preparation for treating cerebral apoplexy and sequelae thereof. The raw materials of the made medicine of the present invention comprise medicinal materials of (by weight percentage) 25% to 40% of hairyvein agrimonia herd, 8% to 18% of lobed kudzuvine root, 15% to 25% of hiraute shiny bugleweed herb, 6% to 10% of chuanxiong rhizome, 2% to 6% of stir-baked froctus gardeniae and 15% to 25% of raw milkvetch root. The present invention belongs to a purely traditional Chinese preparation, and has the action of qi benefiting, activation of blood circulation and channel promotion on cerebral apoplexy and the sequelae thereof. The present invention is mainly used for treating hemiplegia, deviated eyes and mouth, numbness of the limbs, difficult sluggish speech, weakness, vertigo, palpitation, poor sleep, red or faint red tongue, few tongue coatings or no tongue coatings and fine pulse string or deficiency caused by cerebral hemorrhage and cerebral embolism. The present invention conforms to the knowledge of traditional Chinese medicine to the pathogeny of apoplexy. The present invention has the advantages of reasonable formulation, remarkable clinical curative effect and no toxic or side effect on a human body.
Subjects on a 1200 mg salt diet are given placebo pills in order to maintain them on a low salt diet. Subjects then cross-over to the normal sodium condition in the second half of the study.
Approval from Ethical Committee of Faculty of Medicine Universitas Indonesia was acquired prior conducting the study. Subjects were given informed consent before enrolling the study. Intravenous (IV) cannula, non-invasive blood pressure monitor, and pulse-oxymetry were set on the subjects in endoscopic room. Vital signs were recorded. Subjects were then randomized into two groups (three-point Transversus Abdominis Plane \[TAP\] blocks and continuous epidural infusion). The epidural group was received epidural regional anesthesia in sitting position before anesthesia induction, between the first and second lumbar vertebra, with 4 cm depth. The TAP group was received TAP block using ultrasound as a guide and injected in three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points) after the surgery has ended, before the patient was awake. Subjects were given midazolam 0.05 mg/kg body weight (BW) and fentanyl 1-2 µg/kg BW as premedication. Induction was done using propofol 1-2mg/kg BW. Endotracheal intubation was facilitated using atracurium 0.5 mg/kg BW. General anesthesia was maintained using oxygen, air, and sevoflurane. Mechanical ventilation was set with volume control ventilation, Positive End-Expiratory Pressure (PEEP) 5 cm of water, and oxygen fraction of 30-50%. Respiratory rate was set at certain level until the end-tidal carbon dioxide (CO2) value reached around 35-45 mm Hg. During the surgery, the epidural group only received epidural regimen of 0.25% bupivacaine without any adjuvant, while the TAP group received fentanyl and atracurium if needed. After the surgery ended, subjects were prepared for ventilator weaning and extubation. After the subjects were moved to ward, both groups received additional analgesic consisting of fentanyl with patient-controlled analgesia (PCA) method. Total PCA requirements and visual analog scale (VAS) were recorded in the first 24 hours.
Patients receive oral R115777 twice daily for 21 consecutive days. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
A distribution of 40 U (8 U distributed in 5 different areas) of Xeomin Cosmetic over the width of the masseter while respecting the upper limit of the anterior border of the masseter and the inferior insertion of the masseter. The injections are separated by a 1cm distance and the dose is equally distributed across these sites.
The invention discloses an external daily chemical product for preventing and treating alopecia by targeting hair follicle stem cells, which belongs to the technical field of daily chemicals, and the final concentration of the components of the formula is as follows: l-cysteine (1-40mmol/L), resveratrol (5-400. mu. mol/L), alpha-tocopherol (20-600. mu. mol/L), ascorbic acid (4-20mmol/L), astaxanthin (2-50. mu. mol/L), L-lactic acid (1-20mmol/L), and D-biotin (0.5-30. mu. mol/L). The hair follicle stem cells are targeted, the proliferation activity of the hair follicle stem cells is enhanced to 135% at most, and compared with the formula A, the formula B and the formula C on the market, the hair follicle stem cells are improved by over 70%, the cell structure updating speed is improved to resist aging and damage, and the aim of preventing and treating alopecia is fulfilled by aiming at a basic mechanism of hair growth.
The camera recording will be started 5 minutes before the OGT insertion procedure and the routine OGT placement process will be performed. No pain-related procedures are performed during routine OGT in the NICU.
Active substance fraction from Rheum species, to treat and prevent e.g. inflammatory diseases, where the preparation of active substance fraction comprises: extracting dried and ground root samples with methanol; separating lipophilic material from the formed aqueous phase; agitating the purified aqueous phase with ethylacetate; column chromatographically separating the resulting aqueous phase and the combined ethylacetate phase to a limited number of active substance fractions; and condensing the active substance fraction with same content spectrum. Active substance fraction from Rheum species for treating and preventing inflammatory or autoimmune disorder and/or diseases associated with keratinocyte proliferation disturbances, where the preparation of active substance fraction comprises: extracting dried and ground root samples with methanol; separating lipophilic material from the formed aqueous phase under complete removal of methanol; agitating the purified aqueous phase with ethylacetate; separately processing the resulting aqueous phase and the combined ethylacetate phase; column chromatographically separating the resulting aqueous phase and the combined ethylacetate phase to a limited number of active substance fractions; and condensing the active substance fraction with same content spectrum. ACTIVITY : Antiinflammatory; Immunosuppressive; Antiarthritic; Antirheumatic; Gastrointestinal-Gen; Antiulcer; Antipsoriatic; Dermatological; Antimicrobial; Vulnerary. MECHANISM OF ACTION : Interleukin (IL)-1beta and/or IL-2-mRNA-expression inducer; Transforming growth factor (TGF)-beta 1 inducer; IL-1beta or IL-2 suppressor. The ability of the active substance fraction to modulate IL-2-mRNA expression of human phytohaemagglutinin stimulated mononuclear cell. The result showed that the active substance fraction significantly induced the IL-2-mRNA-expression.
The goal of this proposal is to use a recently developed triple-tracer positron emission tomography (PET) method to study skeletal muscle insulin resistance (IR) in research volunteers with type 2 diabetes mellitus (type 2 DM) and in comparison to age and gender-matched, normal weight non-diabetic volunteers, and in comparison to age, gender, and weight-matched overweight or obese non-diabetic volunteers. We will use the three tracers to obtain data on the respective insulin actions upon tissue perfusion, glucose transport and glucose phosphorylation in order to test the hypothesis that insulin resistance (IR) in type 2 DM is caused by an aggregation of impairments at these steps, thus challenging the prevalent concept that IR derives from a solitary impairment in trans-membrane transport.

Proximal steps of glucose transport and phosphorylation are considered to contribute strongly to the pathogenesis of IR in obesity and type 2 DM (1-5). These scientific considerations might have potential therapeutic implications. The overall goal of this project is to provide clarity in separating the respective roles of these proximal steps of glucose metabolism. Glucose transport will be assessed using 11C-3-O-methyl glucose (half-life \~ 20 min; also referred to as 3-0-MG), an analog that is transported but not phosphorylated. 18F-2-deoxy-2-fluoro-glucose (half-life \~ 109 min; also referred to as FDG), will be used to assess glucose transport and glucose phosphorylation. The third tracer that will be used, 15O-H2O, will provide information on tissue perfusion. The challenge with the use of FDG to study insulin action in muscle has been to derive data on two biochemical steps from the tissue activity pattern of a single tracer; this has placed a higher reliance upon the modeling of the data. However, in this project, because of the use of three tracers and the differences in the metabolism of the two glucose analogs, we will be able to address with clear resolution the respective roles of transport and phosphorylation in the pathogenesis of IR in obesity and type 2 DM.
This study is a prospective, parallel controlled clinical trial. Subjects are considered eligible for this study if they meet the inclusion criteria and do not meet any of the exclusion criteria. They must sign an Ethics Committee (EC)-approved Informed Consent Form (ICF) and be randomly assigned to trial group 1, trial group 2 and control group for the respective treatment.

Subjects in Trial Group 1 received polyethylene glycol combined with Vibrabot capsules for 2 weeks and then Vibrabot capsules for 4 weeks; Subjects in Trial Group 2 received Vibrabot capsules for 12 consecutive weeks; Subjects in the control group received polyethylene glycol for 6 weeks, and subjects with poor efficacy could voluntarily choose to continue to receive Vibrabot capsules for 6 weeks. During the treatment period, the dosage of Vibrabot capsule is 1 capsule/time, 5 times/week, and that of polyethylene glycol is 10g/time, twice/day. The subjects who receive Vibrabot capsules will undergo a colonic transit study, a radionuclide imaging-based gastrointestinal transit assessment, an anorectal manometry, a neurotransmitter test, and a fecal flora test before and after the treatment. After completion of treatment, subjects in each group entered a follow-up period, which was observed until the patient regained symptoms of constipation, i.e., when laxatives or other bowel-promoting treatments were used. If the subject never recovered from constipation, a minimum of 8 weeks of questionnaire completion was required, depending on the patient's compliance status. During the study period, the subjects are required to keep an e-diary recording daily bowel movements (BMs), medication intake, and discomforts, and complete the Patient Assessment of Constipation-Symptoms (PAC-SYM) and the Patient Assessment of Constipation Quality of Life (PAC-QOL) questionnaires every two weeks.

This study consists of a screening/baseline period, a treatment period and a follow-up period. During the study, subjects are required not to change their diet and lifestyle. The washout or follow-up period will end once the subject uses rescue medication. If subjects have no BM for three or more consecutive days, they are permitted to take bisacodyl as rescue medication. If they cannot tolerate bisacodyl, an enema may be used instead. They should avoid antibiotics, probiotics, prebiotics, and proton pump inhibitors throughout their participation in the study.
1451008 Selective signalling PERFECT LIBERTY 26 Feb 1974 [28 Feb 1973] 8740/74 Heading G4H Apparatus for collecting medical data comprises a plurality of medical data input units each including a medical data keyboard and a patient I.D. card reader with locking means, a plurality of patient test stations connected to each input unit, a central processing unit connected to receive data from any said input unit and compare the I.D. with the desired I.D. and indicate error or not at the input unit, store the test results and release the locking means at the end of medical tests, medical and I.D. data being reproduced by output means. As disclosed, the central unit selects the input units in turn to supply data to it. The storage addresses of the test results are determined by the I.D. (number). The I.D. is displayed at the input unit for a visual check before the operator permits data transfer. An enquiry station permits retrieval of stored data.
Patients will receive one (1) cycle of atezolizumab, 1200mg intravenously (IV) over 30-60 minutes on day 1 of a 14 day cycle and etrumadenant will be taken at a dose of 150mg PO, once daily, until 48 hours prior to RP, for at least 12 days. Radical Prostatectomy (RP) will occur 21 days (+/- 7 days) following the final dose of atezolizumab. No further study therapy will be administered following RP.
BACKGROUND: It is now realized that Parkinson's disease (PD) pathology extends beyond the substantia nigra, affecting both central and peripheral nervous systems, and exhibits a variety of non-motor symptoms often preceding motor features. Neuroinflammation induced by activated microglia and astrocytes is thought to underlie these manifestations. α-Synuclein aggregation has been linked with sustained neuroinflammation in PD, aggravating neuronal degeneration; however, there is still a lack of critical information about the structural identity of the α-synuclein conformers that activate microglia and/or astrocytes and the molecular pathways involved.
METHODS: To investigate the role of α-synuclein conformers in the development and maintenance of neuroinflammation, we used primary quiescent microglia and astrocytes, post-mortem brain tissues from PD patients and A53T α-synuclein transgenic mice that recapitulate key features of PD-related inflammatory responses in the absence of cell death, i.e., increased levels of pro-inflammatory cytokines and complement proteins. Biochemical and -omics techniques including RNAseq and secretomic analyses, combined with 3D reconstruction of individual astrocytes and live calcium imaging, were used to uncover the molecular mechanisms underlying glial responses in the presence of α-synuclein oligomers in vivo and in vitro.
RESULTS: We found that the presence of SDS-resistant hyper-phosphorylated α-synuclein oligomers, but not monomers, was correlated with sustained inflammatory responses, such as elevated levels of endogenous antibodies and cytokines and microglial activation. Similar oligomeric α-synuclein species were found in post-mortem human brain samples of PD patients but not control individuals. Detailed analysis revealed a decrease in Iba1Low/CD68Low microglia and robust alterations in astrocyte number and morphology including process retraction. Our data indicated an activation of the p38/ATF2 signaling pathway mostly in microglia and a sustained induction of the NF-κB pathway in astrocytes of A53T mice. The sustained NF-κB activity triggered the upregulation of astrocytic T-type Cav3.2 Ca2+ channels, altering the astrocytic secretome and promoting the secretion of IGFBPL1, an IGF-1 binding protein with anti-inflammatory and neuroprotective potential.
CONCLUSIONS: Our work supports a causative link between the neuron-produced α-synuclein oligomers and sustained neuroinflammation in vivo and maps the signaling pathways that are stimulated in microglia and astrocytes. It also highlights the recruitment of astrocytic Cav3.2 channels as a potential neuroprotective mediator against the α-synuclein-induced neuroinflammation.
We report a 9-year-old Japanese girl with chronic non-bacterial osteomyelitis (CNO) accompanied by recurrent erythema nodosum (EN) which was successfully treated with salazosulfapyridine (SASP). She was referred to our hospital because of recurrent erythema on her lower extremities and persistent knee and ankle arthralgia, which had been present for approximately 1 year. Although naproxen, a nonsteroidal anti-inflammatory drug, was initiated, her symptoms frequently recurred. Magnetic resonance imaging demonstrated multiple distinct high-intensity signals in the talus bones suggestive of multiple bone oedemas. Additionally, a histological examination of erythematous lesions was consistent with the histopathological findings of EN. She was diagnosed as having CNO complicated by EN, and received 250 mg/day of SASP as a second-line treatment, which showed partial response of both skin and bone lesions. Following increase in the dose of SASP to 500 mg/day resulted in complete remission of her skin and bone lesions. In conclusion, our findings suggest that SASP is effective not only for CNO bone lesions but also for EN. SASP could serve as a second-line therapeutic option at least for some cases of CNO complicated by EN refractory to nonsteroidal anti-inflammatory drugs.